BARD1 FILES TWO NEW PATENT APPLICATIONS PROTECTING EXPANDED USES OF EXO-NET AND SUBB2M

- **BARD1 has filed 2 new patent applications to protect expanded uses of its EXO-NET and SubB2M technologies**
- **First patent application covers the unique ability of a customised EXO-NET® to capture tumour-derived exosomes from body fluids**
- **Second patent application covers improved SubB2M-based assays to detect cancer with increased specificity and sensitivity**

Melbourne, Australia, 24 May 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) is pleased to announce that two new provisional patent applications have been filed with IP Australia covering expanded uses of its game-changing EXO-NET and SubB2M technologies for cancer diagnosis.

The first patent application entitled 'Methods relating to tumour-derived extracellular vesicles', covers methods of detecting and/or isolating tumour-derived extracellular vesicles from a sample. It uses a customised EXO-NET®, a next generation exosome capture technology, to capture exosomes derived from tumour cells. This exciting invention has enormous potential to improve exosome-associated biomarker discovery in cancer diagnostics and therapeutics.

The second patent application entitled 'Methods of analysing a sample', covers methods of using a supplementary binding molecule in SubB2M-based assays that significantly increases the sensitivity and specificity for cancer detection. Initial studies indicate that these methods can be applied in the analysis of breast and ovarian cancer to achieve close to 100% specificity and sensitivity for all stages of these cancers. This patent application is included under BARD1's exclusive worldwide SubB2M license agreement from the University of Adelaide and Griffith University's Institute for Glycomics.

BARD1 CEO, Dr Leearne Hinch, said: "These two patent applications protect expanded uses for our game-changing EXO-NET and SubB2M platform technologies. The EXO-NET patent application focuses on tumour-derived exosomes and showcases the enormous flexibility of the EXO-NET technology to be modified for various applications to keep pace with new discoveries in the fast-moving exosome field."

BARD1 R&D Manager and inventor of EXO-NET, Dr Emily Stein, said: "This is the first of several planned customised EXO-NETs that we have on the drawing board, making the EXO-NET technology a unique and flexible platform for exosome research and development."

For more information on EXO-NET please visit www.exo-net.com.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@bard1.com
M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions based on its BARD1, SubB2M, and Molecular NETs platforms for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology and development-stage tests for ovarian, breast, prostate and pancreatic cancers. The Company is also commercialising its Molecular NETs platform for sample preparation and has launched its first proprietary EXO-NET® exosome capture tool for

use in research for exosome-based diagnostics and therapeutics. For more information on BARD1 and EXO-NET, visit www.bard1.com and www.exo-net.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements